Full history for every metric is available with a Kvantra account
Ortho Clinical Diagnostics Holdings plc (OCDX)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | 1,782 | 1,787 | 1,802 | 1,766 | 2,043 | 2,036 |
| Operating profit | $m | 120 | 162 | |||||
| Net profit | $m | - | -116 | -249 | -157 | -212 | -54 | -0 |
| EPS reported | $ | -0.22 | -0.01 | |||||
| Operating cashflow per share | $ | 1.18 | 1.18 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | 1.18 | 1.18 | |||||
| Free cash flow | $m | 287 | 252 | |||||
| Net debt | $m | 1,940 | 1,959 | |||||
| Book value equity | $m | 411 | 443 | |||||
| Book value per share | $ | 1.69 | 1.83 | |||||
| Number of shares | m | 242.8 | 242 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 12.49 | 9.62 | |||||
| P/S LTM | x | 2.51 | 2.10 | |||||
| P/FCF LTM | x | 17.89 | 16.95 | |||||
| EV/EBITDA LTM | x | 27.89 | 14.32 | |||||
| EV/Sales LTM | x | 3.46 | 3.06 | |||||
| Earnings Yield LTM | % | -1.06% | -1.27% | |||||
| FCF Yield | % | 5.59% | 5.90% | |||||
| Quality | ||||||||
| ROE | % | -13.23% | 18.09% | |||||
| ROIC | % | 4.21% | 4.21% | |||||
| Operating margin | % | 5.87% | 5.87% | |||||
| Gross margin | % | 50.71% | 50.71% | |||||
| FCF/Sales | % | 14.03% | 14.03% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +15.66% | +9.17% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | +1660.1% | |||||
| Operating Profit Growth | % | +35.90% | +21.00% | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.13 | 0.11 | |||||
| Net Debt/EBITDA | x | 7.66 | 7.66 | |||||
| EBIT/Net interest | x | 0.82 | 0.82 | |||||
| Net debt/market cap | % | 37.84% | 45.92% | |||||
| Net debt/Equity | x | 4.73 | 4.42 | |||||
| Gross debt/equity | x | 5.48 | 5.08 | |||||
Company overview
Ortho Clinical Diagnostics Holdings plc, established in 1939 and based in Raritan, New Jersey, operates as a global provider of in-vitro diagnostic solutions. The company caters to both clinical laboratories and the transfusion medicine community, offering a comprehensive range of automated instruments together with the assays, reagents, and consumables required to produce test results. Their product portfolio includes clinical chemistry and immunoassay systems designed to detect and track disease progression across various therapeutic conditions, notably featuring tests for COVID-19 antibodies and antigens. Additionally, Ortho Clinical Diagnostics provides immunohematology instruments and tests crucial for blood typing, ensuring patient-donor compatibility during transfusions, along with donor screening tools to identify infectious diseases in blood and plasma. Beyond diagnostic products, the company also engages in contract manufacturing and orthocare services. Its offerings are widely deployed in hospitals, laboratories, clinics, blood banks, and donor centers.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Ortho Clinical Diagnostics Holdings plc (OCDX)
Ortho Clinical Diagnostics Holdings plc, established in 1939 and based in Raritan, New Jersey, operates as a global provider of in-vitro diagnostic solutions. The company caters to both clinical laboratories and the transfusion medicine community, offering a comprehensive range of automated instruments together with the assays, reagents, and consumables required to produce test results. Their product portfolio includes clinical chemistry and immunoassay systems designed to detect and track disease progression across various therapeutic conditions, notably featuring tests for COVID-19 antibodies and antigens. Additionally, Ortho Clinical Diagnostics provides immunohematology instruments and tests crucial for blood typing, ensuring patient-donor compatibility during transfusions, along with donor screening tools to identify infectious diseases in blood and plasma. Beyond diagnostic products, the company also engages in contract manufacturing and orthocare services. Its offerings are widely deployed in hospitals, laboratories, clinics, blood banks, and donor centers.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free